Dynavax Technologies Corp
Day Range: 10.36 - 11.00
Last Trade Time: 7:59:16 PM EDT
Total Trades: 12,653
DVAX Detailed Quote
Clover’s COVID-19 Vaccine Candidate Demonstrates Strong Cross-Neutralization Against Omicron as a Homologous Booster • GlobeNewswire Inc. • 06/27/2022 10:04:28 AM
Clover Doses First Participants in Phase 3 Trial Evaluating SCB-2019 as a Heterologous COVID-19 Booster Following Prior Vaccination with Inactivated,
$DVAX, Friday Sept 24, We are UP 1.17% and AH Up 0.71%
$DVAX Next Week - Up Again ?
Surging Dynavax Stock Could Soar Even Higher
Wed, September 22, 2021, 2:00 PM·2 min read
Biopharmaceutical concern Dynavax Technologies Corporation (NASDAQ:DVAX) is up 33.9% to trade at $19.90 this afternoon. This surge comes after news broke that Clover Biopharmaceuticals reported its Covid-19 vaccine candidate, which utilizes Dynavax's CpG 1018 adjuvant, was 67% overall effective against Covid-19 and 79% against the Delta variant. Even better, DVAX recently pulled back to a trendline with historically bullish implications, giving investors plenty of reason to believe that the stock could soon surge even higher on the charts.
Specifically, Dynavax stock just came within one standard deviation of the 40-day moving average, after spending much of the last three months above this trendline. According to data from Schaeffer's Senior Quantitative Analyst Rocky White, six similar signals have occurred in the past three years. The security enjoyed a positive return one month later in 60% of those cases, averaging a 22.9% gain. From its current perch, a similar move would put DVAX near the $24.45 mark, which represents territory not seen since early 2016.
On the charts, the security managed to reclaim a fresh three-year peak of $20.66. Today's positive price action also has DVAX pacing for a close above the 20-day moving average, after seven-straight closes below the trendline. Year-to-date, Dynavax stock boasts a 352.1% lead.
Options traders are bombarding the stock following today's vaccine news. So far, over 25,000 calls and 5,831 puts have exchanged hands, which is five times the intraday average. The most popular contract is the October 20 call, while new positions are being opened at the 19 call from the same series.
Short sellers have already been building their positions as well. Short interest has grown 22.2% in the last two reporting periods, and the 23.21 million shares sold short make up a healthy 20.3% of the equity's available float, or over six days' worth of pent-up buying power.
New potential....new opportunities!! Ziggy
Unfortunately UK's just announced termination order as of this morning will cause stock to drop back to $12 from a recent high of $19.
Good luck to all....ziggy.
Still holding 1k shares for now
Someone has been accumulating...I see 200k share or more buys the last several days....
Presentation next week at big conference
I'm still waiting but have some conditional buys ready in case
Probably...but we will see
We are developing cutting-edge vaccines by utilizing our innovative adjuvant technology and our expertise of Toll-like Receptor (TLR) biology to modulate the immune system.
[HEPATITIS B VACCINE (RECOMBINANT) ADJUVANTED]
During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas
– these include safeguarding the health and safety of our employees and customers; continuing effective operations
to ensure patient access to HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted]; maintaining our financial strength and stability;
and supporting efforts to develop a COVID-19 vaccine.